Exacerbations of chronic obstructive pulmonary disease

Proceedings of the American Thoracic Society

Volumn 4, Issue 7, 2007, Pages 554-564

  Anzueto, Antonio ^a   Sethi, Sanjay ^b   Martinez, Fernando J ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Acute exacerbations; Antibiotics; Chronic obstructive pulmonary disease; Haemophilus influenzae; Streptococcus pneumoniae

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FORMOTEROL; METHYLPREDNISOLONE; METHYLXANTHINE; PLACEBO; PREDNISONE; SALMETEROL; STEROID; TIOTROPIUM BROMIDE;

BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATION; BRONCHOSCOPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; FOLLOW UP; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MONOTHERAPY; MORBIDITY; MORTALITY; MULTIPLE REGRESSION; OXYGEN THERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BRONCHODILATOR AGENTS; HUMANS; POSITIVE-PRESSURE RESPIRATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RISK FACTORS; VIRUS DISEASES;

EID: 35148813000     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200701-003FM     Document Type: Review

References (116)

1. National Heart, Lung, and Blood Institute. Morbidity & mortality: 2002 chart book on cardiovascular, lung, and blood diseases. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health; 2002. Available from: http://www.nhlbi.nih.gov/resources/docs/02_chtbk.pdf (accessed September 19, 2002).
2. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Surveill Summ 2002;51:1-16.
3. GOLD Executive and Science Committees. Executive summary: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; December 2006. Available from: http://www.goldcopd.org/Guidelineitem. asp?l1=2&l2=1&intId=996 (accessed March 14, 2007).
4. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946.
5. Miravitlles M, Murio C, Guerrero T, Gisbert R; DAFNE Study Group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002;121:1449-1455.
6. Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, Verea H, Murio C, Ros F, Vidal R; IMPAC Study Group. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004;59:387-395.
7. Rutshmann OT, Cornuz J, Poletti PA, Bridevaux PO, Hugli OW, Qanadli SD, Perrier A. Should pulmonary embolisms be suspected in exacerbation of chronic obstructive pulmonary disease? Thorax 2007;62:121-125.
8. Tillie-Leblond I, Marquette CH, Perez T. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 2006;144:390-396.
9. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;20:1297-1303.
10. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998;351:773-780.
11. Donaldson GC, Seemungal TAR, Bhomik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-852.
12. Greenberg SB, Allen MA, Wilson J, Atmar RL. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:167-173.
13. Miravitlles M, Mayordomo C, Artés M, Sánchez-Agudo L, Nicolau F, Segú JL. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice: EOLO Group. Observational de la Limitacion Obstructiva al Flujo a Ereo. Respir Med 1999;93:173-179.
14. Gompertz S, Bayley DL, Hill SL, Stockley RA. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001;56:36-41.
15. Miravitlles M, Guerrero T, Mayordomo C, Sánchez-Agudo L, Nicolau F, Segú JL. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration (Herrlisheim) 2000;67:495-501.
16. Dewan NA, Rafique S, Kanwar B, Satpathy H, Ryschon K, Tillotson GS, Niederman KS. Acute exacerbation of COPD: factors associated with poor outcome. Chest 2000;117:662-671.
17. Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000;117:1345-1352.
18. Murata GH, Gorby MS, Kapsner CO, Chick TW, Halperin AK. A multivariate model for predicting hospital admissions for patients with decompensate chronic obstructive pulmonary disease. Arch Intern Med 1992;152:82-86.
19. Antonelli Incalzi R, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, Pistelli R. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997;10:2794-2800.
20. Vilkman S, Keistinen T, Tuuponen T, Kivelä SL. Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital. Respiration (Herrlisheim) 1997;64:281-284.
21. Hodgev VA, Kastianev SS, Torosian AA, Yanev IB, Mandoulova PB. Long-term changes dyspnea, lung function, and exercise capacity in COPD patients. Folia Med (Plovdiv) 2004;46:12-17.
22. Spencer S, Jones PW, for the GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003;58:589-593.
23. Spencer S, Calverley PMA, Burge S, Jones PW, ISOLDE Study Group. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:122-128.
24. Donaldson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA. Exacerbations and time spend outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:446-452.
25. Connors AF Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA. Outcomes following acute exacerbation of severe chronic obstructive lung disease: the SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996;154:959-967.
26. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-1613.
27. Crooks SW, Bayley DL, Hill SL, Stockley RA. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J 2000;15:274-280.
28. Ras G, Wilson R, Todd H, Taylor G, Cole PJ. The effect of bacterial products on neutrophil migration in vitro. Thorax 1990;45:276-280.
29. 1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996;51:267-271.
30. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, Fabbri LM, Johnston SL. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-1121.
31. Zhu J, Qiu YS, Majumdar S, Gamble E, Matin D, Turato G, Fabbri LM, Barnes N, Saetta M, Jeffery PK. Exacerbations of bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med 2001;164:109-116.
32. Sethi S, Muscarella K, Evans N, Klingman KL, Grant BJB, Murphy TF. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000;118:1557-1565.
33. Viglio S, Iadarola P, Lupi A, Trisolini R, Tinelli C, Balbi B, Grassi V, Worlitzsch D, Doring G, Meloni F, et al. MEKC of desmosine and isodesmosine in urine of chronic destructive lung disease patients. Eur Respir J 2000;15:1039-1045.
34. Gompertz S, O'Brien C, Bayley DL, Hill SL, Stockley RA. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001;17:1112-1119.
35. Gottlieb DJ, Stone PJ, Sparrow D, Gale ME, Weiss ST, Snider GL, O'Connor GT. Urinary desmosine excretion in smokers with and without rapid decline of lung function: the Normative Aging Study. Am J Respir Crit Care Med 1996;154:1290-1295.
36. Kosmas EN, Zorpidou D, Vassilareas V, Roussou T, Michaelides S. Decreased C4 complement component serum levels correlate with the degree of emphysema in patients with chronic bronchitis. Chest 1997;112:341-347.
37. Aaron SD, Vandemheen KL, Clinch JJ, Ahuja J, Brison RJ, Dickinson G, Hébert PC. Measurment of short-term changes in dyspnoea and disease-specific quality of life following an acute COPD exacerbation. Chest 2002;121:688-696.
38. Andersson I, Johansson K, Larsson S, Pehrsson K. Long-term oxygen therapy and quality of life in elderly patients hospitalised due to severe exacerbation of COPD: a 1 year follow-up study. Respir Med 2002;96:944-949.
39. Miravitlles M, Jardim JR, Zitto T, Rodrigues JE, López H. Pharmacoeconomic study of antibiotic therapy for acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Arch Bronconeumol 2003;39:549-553.
40. Friedman M, Hilleman DE. Economic burden of chronic obstructive pulmonary disease. Pharmacoeconomics 2001;19:245-254.
41. Almagro P, Calbo E, Ochoa de Echaguen A, Barreiro B, Quintana S, Heredia JL, Garau J. Mortality after hospitalization for COPD. Chest 2002;121:1441-1448.
42. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003;124:459-467.
43. Fuso L, Incalzi RA, Pistelli R, Muzzolon R, Valente S, Pagliari G, Gliozzi F, Ciappi G. Predicting mortality of patients hospitalized for acute exacerbated chronic obstructive pulmonary disease. Am J Med 1995;98:272-277.
44. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-931.
45. Balbi B, Bason C, Balleari E, Fiasella F, Pesci A, Ghio R, Fabiano F. Increased bronchoalveolar granulocytes and granulocyte-macrophage colony-stimulating factor during exacerbations of chronic bronchitis. Eur Respir J 1997;10:846-850.
46. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:71-78.
47. Wouters EF. Chronic obstructive pulmonary disease. 5: systemic effects of COPD. Thorax 2002;57:1067-1070.
48. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, Jeffries DJ, Meade TW. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000;84:210-215.
49. Dev D, Wallace E, Sankaran R, Cunniffe J, Govan JR, Wathen CG, Emmanuel FX. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med 1998;92:664-667.
50. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Muller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004;363:600-607.
51. Anthonisen NR, Manfreda J, Warren CPW, Hersh.eld ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
52. Veeramachaneni SB, Sethi S. Pathogenesis of bacterial exacerbations of COPD. COPD 2006;3:109-115.
53. Sethi S, Evans N, Grant BJB, Murphy TF. Acquisition of a new bacterial strain and occurrence of exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-471.
54. Chin CL, Manzel LJ, Lehman EE, Humlicek AL, Shi L, Starner TD, Denning GM, Murphy TF, Sethi S, Look DC. Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med 2005;172:85-91.
55. Fernaays MM, Lesse AJ, Sethi S, Cai X, Murphy TF. Differential genome contents of nontypeable Haemophilus influenzae strains from adults with chronic obstructive pulmonary disease. Infect Immun 2006;74:3366-3374.
56. Murphy TF, Brauer AL, Grant BJ, Sethi S. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 2005;172:195-199.
57. Abe Y, Murphy TF, Sethi S, Faden HS, Dmochowski J, Harabuchi Y, Thanavala YM. Lymphocyte proliferative response to P6 of Haemophilus influenzae is associated with relative protection from exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165:967-971.
58. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000;117:1638-1645.
59. White AJ, Gompertz S, Bayley DL, Hill SL, O'Brien C, Unsal I, Stockley RA. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003;58:680-685.
60. Yi K, Sethi S, Murphy T. Human immune response to nontypeable Haemophilus influenzae in chronic bronchitis. J Infect Dis 1997;176:1247-1252.
61. Sethi S, Wrona C, Grant B, Murphy T. Strain specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:448-453.
62. Bogaert D, van der Valk P, Ramdin R, Sluijter M, Monninkhof E, Hendrix R, de Groot R, Hermans PW. Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infect Immun 2004;2:818-823.
63. Aaron SD, Ramotar K, Ferris W, Vandemheen K, Saginur R, Tullis E, Haase D, Kottachchi D, St Deni M, Chan F. Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2004;169:811-815.
64. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-951.
65. Seemungal TA, Harper-Owen R, Bhowmik A, Jeffries DJ, Wedzicha JA. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J 2000;16:677-683.
66. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, Maccallum P, Meade TW, Jeffries DJ, Johnston SL, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1618-1623.
67. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005;352:1749-1759.
68. Blasi F, Damato S, Cosentini R, Tarsia P, Raccanelli R, Centanni S, Allegra L. Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment. Thorax 2002;57:672-676.
69. Mogulkoc N, Karakurt S, Isalska B, Bayindir U, Celikel T, Korten V, Colpan N. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med 1999;160:349-353.
70. Miyashita N, Niki Y, Nakajima M, Kawane H, Matsushima T. Chlamydia pneumoniae infections in patients with diffuse panbronchiolitis and COPD. Chest 1998;114:969-971.
71. Karnak D, Beng-sun S, Beder S, Kayacan O. Chlamydia pneumoniae infection and acute exacerbation of chronic obstructive pulmonary disease (COPD). Respir Med 2001;95:811-816.
72. Beaty CD, Grayston JT, Wang SP, Kuo CC, Reto CS, Martin TR. Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991;144:1408-1410.
73. Blasi F, Legnani D, Lombardo VM, Negretto GG, Magliano E, Pozzoli R, Chiodo F, Fasoli A, Allegra L. Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 1993;6:19-22.
74. Smith CB, Golden C, Kanner R, Renzetti AD Jr. Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases. Am Rev Respir Dis 1980;121:225-232.
75. Wilkinson T, Hurst J, Perera W, Wilks M, Donaldson G, Wedzicha J. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of chronic obstructive pulmonary disease. Chest 2006;129:317-324.
76. Bandi V, Apicella MA, Mason E, Murphy TF, Siddiqi A, Atmar RL, Greenberg SB. Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med 2001;164:2114-2119.
77. Sethi S. Co-infection in exacerbations of COPD: a new frontier. Chest 2006;129:223-224.
78. Carrera M, Sala E, Cosio BG, Agusti AG. Hospital treatment of chronic obstructive pulmonary disease exacerbation: an evidence-based review. Arch Bronconeumol 2005;41:220-229.
79. McCrory DC, Brown CD. Anti-cholinergic bronchodilators versus -β2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002;4:CD003900.
80. MacNee W. Acute exacerbations of COPD. Swiss Med Wkly 2003;133:247-257.
81. Niewoehner D. The role of systemic corticosteroids in acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Med 2002;1:243-248.
82. Wood-Baker RR, Gibson PG, Hannay M, Walters EH, Walters JAE. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;1:CD001288.
83. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA. Effect of sytemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease: Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999;304:1941-1947.
84. Sayiner A, Aytemur ZA, Cirio M, Unsal I. Systemic glucocorticoids in severe exacerbations of COPD. Chest 2001;119:726-730.
85. Davies L, Angus R, Calverley P. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999;354:456-460.
86. Thompson WH, Nelson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996;154:407-412.
87. Aaron SD, Vandemheen KL, Herbert P, Dales R, Stiell IG, Ahuja J, Dickerson G, Brison R, Rowe BH, Dreyer J, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003;348:2618-2625.
88. Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:1298-1303.
89. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease: national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59:1-232.
90. Cydulka RK, Rowe BH, Clark S, Emerman CL, Camargo CA Jr, Investigators MARC. Emergency department management of acute exacerbationis of chronic obstructive pulmonary disease in the elderly: the Multicenter Airway Research Consortium. J Am Geriatr Soc 2003;51:908-916.
91. Lindenauer PK, Pekow P, Gao S, Crawford AS, Gutierrez B, Benjamýn EM. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2006;144:894-903.
92. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995;273:957-960.
93. Ram FSF, Rodrýguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;2:CD004403.
94. Martinez FJ, Han MK, Flaherty K, Curtis J. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert Rev Anti Infect Ther 2006;4:101-124.
95. Blasi F, Ewig S, Torres A, Huchon G. A review of guidelines for antibacterial use in acute exacerbations of chronic bronchitis. Pulm Pharmacol Ther 2006;19:361-369.
96. Allegra L, Blasi F, Diano P, Cosentini R, Tarsia P, Confalonieri M, Dimakou K, Valenti V. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med 2005;99:742-747.
97. Christ-Crain M, Jaccard-Stoltz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Muller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded interventionl trial. Lancet 2004;363:600-607.
98. Stolz D, Christ-Crain M, Gencay MM, Bingisser R, Huber PR, Müller B, Tamm M. Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infection. Swiss Med Wkly 2006;136:434-440.
99. Maruna P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin. Physiol Res 2000;49:S57-S61.
100. Stolz D, Chris-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, Huber P, Muller B, Tamm M. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007;131:9-19.
101. Martinez F, Curtis J. Procalcitonin-guided antibiotic therapy in COPD exacerbations: closer but not quite there yet. Chest 2007;131:1.
102. Martinez F. The impact of antimicrobial resistance: patterns for common respiratory pathogens. Consultant 2002;4:S1-S6.
103. Perez-Trallero E, Marimón JM, González A, Ercibengoa M, Julián Larruskain J. in vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease. Clin Infect Dis 2005;41:560-564.
104. Ho PL, Tse WS, Tsang KW, Kwok TK, Ng TK, Cheng VC, Chan RM. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001;32:701-707.
105. Weiss K, Restieri C, Gauthier R, Laverdiere M, McGeer A, Davidson RJ, Kilburn L, Bast DJ, de Azavedo J, Low DE. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin Infect Dis 2001;33:517-522.
106. Martinez FJ, Grossman RF, Zadeikis N, Fisher AC, Walker K, Ambruzs ME, Tennenberg AM. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur Respir J 2005;25:1001-1010.
107. McCrory DC, Brown C, Gelfand SE, Back PB. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest 2001;119:1190-1209.
108. Stoller J. Acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;346:988-994.
109. Ram FSF, Picot J, Lightowler J, Wedzicha JA. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2004;3:CD004104.
110. American Thoracic Society. International Consensus Conference in Intensive Care Medicine: noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 2001;163:283-291.
111. Sinuff T, Keenan S. Clinical practice guideline for the use of noninvasive positive pressure ventilation in COPD patients with acute respiratory failure. J Crit Care 2004;19:82-91.
112. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;15:957-965.
113. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JAD Jr, Korducki L, Cassino C, Kesten S. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergics bronchodilator. Ann Intern Med 2005;143:319-326.
114. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006;27:547-555.
115. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003;124:834-843.
116. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators. Salmeterol and fluticasone proprionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789.